Correction to: Cost‐Effectiveness of Icosapent Ethyl in REDUCE‐IT USA: Results From Patients Randomized in the United States
Saved in:
| Format: | Article |
|---|---|
| Language: | English |
| Published: |
Wiley
2024-04-01
|
| Series: | Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease |
| Online Access: | https://www.ahajournals.org/doi/10.1161/JAHA.123.027774 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Icosapent ethyl: scientific and legal controversies
by: Gregory Curfman, et al.
Published: (2021-02-01) -
Cross-Sectional analysis of demographic and clinical characteristics of patients in the United States using icosapent ethyl
by: Peter P. Toth, et al.
Published: (2025-03-01) -
Cardiovascular Outcomes With Icosapent Ethyl by Baseline Low‐Density Lipoprotein Cholesterol: A Secondary Analysis of the REDUCE‐IT Randomized Trial
by: Rahul Aggarwal, et al.
Published: (2025-03-01) -
Comparative Risk of Atrial Fibrillation Onset in Statin‐Treated Patients Initiating Icosapent Ethyl and Omega‐3 Acid Ethyl Esters: A Retrospective Cohort Study
by: Jyotirmoy Sarker, et al.
Published: (2025-08-01) -
The First Clinical and Functional Results of Myopia Correction Using a Solid-State Laser Unit
by: N. V. Maychuk, et al.
Published: (2023-10-01)